Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant

NCT04543591 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

148

Enrollment

INDUSTRY

Sponsor class

Conditions

Thrombotic Microangiopathy

Interventions

BIOLOGICAL: Ravulizumab
OTHER: Placebo
OTHER: Best supportive care

Sponsor

Alexion Pharmaceuticals, Inc.